Riskpilot← Back to searchSign inGet full accessPharma Gateway AB
ABActiveOrg 5569805723Torshamnsgatan 28 ABusiness and other management consultancy activities · NACE 7020Est. 20141 employees
Revenue 2025
SEK 1,6M
+13% vs 2024
EBITDA margin
24.0%
-30% vs 2024
Equity ratio
42.0%
Financial strength
Net profit 2025
SEK 223K
-51% vs 2024
| Revenue | SEK 1,6M | +13% |
| EBITDA | SEK 374K | -30% |
| Net profit | SEK 223K | -51% |
| Total assets | SEK 935K | +70% |
| Equity | SEK 392K | +132% |
| Employees | 1 | — |
Legal name
Pharma Gateway AB
Org number
5569805723
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
25 augusti 2014
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska agera representant för internationella läkemedelsföretag vid interaktioner med läkemedelsmyndigheter.
Address
Torshamnsgatan 28 A
Email
info@pharmagateway.eu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 157 | 819 | 819 | 423 | 465 | 44 | 1 373 | 1 554 |
| Staff expenses | — | — | — | — | — | — | — | — | — | −6 | −20 |
| EBITDA | −3 | 34 | 52 | 57 | 409 | 564 | 405 | 453 | −330 | 534 | 374 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — |
| EBIT | −3 | 34 | 52 | 57 | 409 | 564 | 405 | 453 | −330 | 534 | 374 |
| Net financials | — | — | — | — | — | — | — | — | −4 | 0 | 1 |
| Profit before tax | −3 | 34 | 39 | 42 | 37 | 43 | 29 | 453 | −334 | 484 | 281 |
| Tax | −0 | −7 | −9 | −9 | −8 | −9 | −6 | −93 | — | −31 | −58 |
| Net profit | −3 | 27 | 30 | 33 | 29 | 34 | 23 | 360 | −334 | 453 | 223 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 47 | 82 | 126 | 175 | 574 | 770 | 608 | 677 | 326 | 552 | 935 |
| Equity | 47 | 74 | 105 | 138 | 167 | 201 | 224 | 584 | −284 | 170 | 392 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Short-term debt | 0 | 8 | 8 | 10 | 368 | 569 | 384 | 93 | 610 | 332 | 399 |
| Total debt | — | 8 | 8 | 10 | 368 | 569 | 384 | 93 | 610 | 332 | 399 |
EBITDA margin
24.0%
This company
15.8%
Market median
+52% vs market
20152025
Equity ratio
42.0%
This company
38.2%
Market median
+10% vs market
20152025
Return on equity
56.8%
This company
18.4%
Market median
+209% vs market
20152025
Net profit margin
14.3%
This company
8.1%
Market median
+77% vs market
20152025
Asset turnover
1.66×
This company
1.12×
Market median
+48% vs market
20152025
Debt / equity
1.38×
This company
0.62×
Market median
-123% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-08-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ME External Signatory | External Signatory | 2022 | — | — |
HS External Signatory | External Signatory | 2020 | — | — |
AM External Signatory | External Signatory | 2020 | — | — |
UP Audit | Audit | 2023 | — | — |
RP External Signatory | External Signatory | 2020 | — | — |
BA External Signatory | External Signatory | 2022 | — | — |
TS External Signatory | External Signatory | 2022 | — | — |
EC Auditor Substitute | Auditor Substitute | 2023 | — | — |
LJ Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
JN Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NKB Consulting AB | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NKB Consulting AB
Pharma Gateway AB Board members of Pharma Gateway AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Elisabeth Nilsson Hagberg | External Signatory | 0 companies |
| Helen Scrivener | External Signatory | 0 companies |
| Anna Maria Leitgeb | External Signatory | 0 companies |
| Ulf Peter Johansson | Audit | 0 companies |
| Rainer Paffenholz | External Signatory | 0 companies |
| Björn Andreas Carlsson | External Signatory | 0 companies |
| Tiina Seppä | External Signatory | 0 companies |
| Eva Cajsa Marcelius | Auditor Substitute | 0 companies |
| Lars Johan Strömqvist | Chief Executive Officer | 0 companies |
| Johan Niklas Bendelius | Chief Executive Officer | 0 companies |
| Lars Helge Strömqvist | Board of Directors | 0 companies |
| Ingrid Christina Strömqvist | Deputy Board Member | 0 companies |
| Karin Anna Ingrid Bendelius | Deputy Board Member | 0 companies |